Strategic funding BioSurfaces recently secured a $2.06 million grant from the Bill & Melinda Gates Foundation to support development of an implant device for chronic illness, highlighting potential for grant-backed collaboration, co-development, or funded pilot programs with health-focused organizations and NGOs.

GI disease focus Historical collaboration with Takeda on GI disease medical devices suggests established interest and credibility in gastrointestinal therapeutic devices, presenting opportunities to approach large pharma and device companies for co-development, licensing, or expansion into related GI indications.

Nanofiber advantage Bio-Spun® electrospinning technology enables localized drug release within nanofibers and customizable shapes, creating a compelling value proposition for pharmaceutical, device, and consumer health partners seeking advanced biomaterials and targeted delivery solutions.

Small team agility With a lean workforce (11-50) and a track record of collaborating with major industry players, BioSurfaces offers a nimble partner for rapid pilots, flexible contract research, manufacturing collaboration, and outsourced development programs.

Validated by leaders Active validation by leading organizations in pharma, medical devices, life sciences, and consumer products, combined with public funding, signals credibility for enterprise partnerships, tiered engagements, and scalable manufacturing collaborations.